These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 28652891)

  • 1. Non-alcoholic fatty liver disease: An expanded review.
    Benedict M; Zhang X
    World J Hepatol; 2017 Jun; 9(16):715-732. PubMed ID: 28652891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease - current status and future directions.
    Demir M; Lang S; Steffen HM
    J Dig Dis; 2015 Oct; 16(10):541-57. PubMed ID: 26406351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growing challenge of post-liver transplantation non-alcoholic fatty liver disease.
    Kalogirou MS; Giouleme O
    World J Transplant; 2022 Sep; 12(9):281-287. PubMed ID: 36187880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease: The diagnosis and management.
    Abd El-Kader SM; El-Den Ashmawy EM
    World J Hepatol; 2015 Apr; 7(6):846-58. PubMed ID: 25937862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pediatric non-alcoholic fatty liver disease: recent advances and challenges].
    Poggiogalle E; Olivero G; Anania C; Ferraro F; Pacifico L
    Minerva Pediatr; 2010 Dec; 62(6):569-84. PubMed ID: 21042270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
    Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
    JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of non-alcoholic fatty liver disease.
    Cataldo I; Sarcognato S; Sacchi D; Cacciatore M; Baciorri F; Mangia A; Cazzagon N; Guido M
    Pathologica; 2021 Jun; 113(3):194-202. PubMed ID: 34294937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease.
    Powell EE; Wong VW; Rinella M
    Lancet; 2021 Jun; 397(10290):2212-2224. PubMed ID: 33894145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
    Sharma N; Chakole S; Wandile B
    Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.
    Wong SW; Ting YW; Chan WK
    JGH Open; 2018 Oct; 2(5):235-241. PubMed ID: 30483595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.